Related Experiment Video
Updated: Feb 10, 2026
05:52
Insulin Injection and Hemolymph Extraction to Measure Insulin Sensitivity in Adult Drosophila melanogaster
Published on: June 30, 2011
20.4K
Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).
Sanjay Kalra1, Stephen Atkin2, Antonio Cervera3
1Department of Endocrinology, Bharti Hospital Karnal, Karnal, India. brideknl@gmail.com.
Advances in Therapy
|May 26, 2018
Summary
Insulin degludec/aspart (IDegAsp) offers improved long-term glycemic control for type 2 diabetes patients. This co-formulation demonstrates effectiveness and convenience for both type 1 and type 2 diabetes management.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Insulin therapy is crucial for managing diabetes.
- Current insulin regimens may present challenges in efficacy and patient adherence.
- Novel insulin formulations aim to improve glycemic control and reduce adverse events.
Purpose of the Study:
- To evaluate the efficacy and safety of insulin degludec/aspart (IDegAsp) in patients with type 1 and type 2 diabetes.
- To compare IDegAsp with other insulin therapies for glycemic control and hypoglycemia rates.
Main Methods:
- Clinical trials involving patients with type 2 diabetes inadequately controlled with oral agents.
- Studies in type 2 diabetes patients previously treated with insulin.
- Evaluation of IDegAsp in type 1 diabetes patients compared to conventional basal-bolus therapy.
Main Results:
- IDegAsp once daily improved long-term glycemic control in type 2 diabetes compared to insulin glargine, with similar fasting plasma glucose and insulin doses.
- IDegAsp demonstrated numerically lower rates of overall and nocturnal hypoglycemia.
- Twice-daily IDegAsp improved glycated hemoglobin and fasting plasma glucose in type 2 diabetes patients with fewer hypoglycemic episodes than premix or basal-bolus therapies.
- IDegAsp offers a convenient and effective regimen for type 1 diabetes.
Conclusions:
- Insulin degludec/aspart (IDegAsp) is a valuable therapeutic option for initiating insulin therapy in both type 1 and type 2 diabetes.
- IDegAsp provides superior long-term glycemic control and favorable safety profiles, including reduced hypoglycemia.
- The co-formulation offers flexibility and convenience for diabetes management.
Related Concept Videos
01:05Insulin Secretory Vesicles
7.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
7.0K
01:28Insulin: The Receptor and Signaling Pathways
3.4K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
3.4K
01:27Insulin Formulations: Types and Delivery
781
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
781
01:25Insulin: Biosynthesis, Chemistry, and Preparation
1.4K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.4K
01:16Insulin: Dosing Regimen and Adverse Effects
825
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
825
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.6K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.6K